Past and present scenario of imaging infection and inflammation: a nuclear medicine perspective

AbstractNuclear medicine techniques provide potential non-invasive tools for imaging infections and inflammations in the body in a precise way. These techniques are further exploited by the use of radiopharmaceuticals in conjunction with imaging tests such as scintigraphy and positron emission tomography. Improved agents for targeting infection exploit the specific accumulation of radiolabeled compounds to understand the pathophysiologic changes involved in the inflammatory process and correlate them with other chronic illnesses. In the recent past, a wide variety of radiopharmaceuticals have been developed, broadly classified as specific radiopharmaceuticals and nonspecific radiopharmaceuticals. New developments in positron emission (leveraging 18F and 18fluorodeoxyglucose) and heterocyclic/peptide chemistry and radiochemistry are resulting in unique agents with high specific activity. Various approaches to visualizing infection and inflammation are presented in this review, in an integral manner, that give a clear view of the existing radiopharmaceuticals in clinical practice and those under development.     

Past and present concepts in flow cytometry: a European perspective

The development of flow cytometric instrumentation, methods and research concepts in Europe has been a continuous driving force for the general scientific advancement in this area over the years. This review addresses early European concepts of continuing interest with regard to instrumentation, data analysis, clinical and eperimental DNA analysis, cell function and microbiology at their worldwide first appearence while flow cytometric immunology and immunophenotyping will be covered separately. Flow cytometry represents an efficient approach to the enormous complexity of molecular cell architecture and cell function by the analysis of apparent molecular cell phenotypes in heterogeneous cell samples. The present merger of flow and image cytometry into the method independent cytomics discipline increases the potential of cell analysis very significantly. It opens the way for predictive medicine as well as for predictive cytopathology and predictive cytology in everyday clinical and medical practice. Current progress is driven by joint advances in molecular fluorescence technologies and instrument development. This complements the analysis of genome sequence information in an efficient way.     

Molecular-genetic imaging: a nuclear medicine-based perspective

Molecular imaging is a relatively new discipline, which developed over the past decade, initially driven by in situ reporter imaging technology. Noninvasive in vivo molecular-genetic imaging developed more recently and is based on nuclear (positron emission tomography [PET], gamma camera, autoradiography) imaging as well as magnetic resonance (MR) and in vivo optical imaging. Molecular-genetic imaging has its roots in both molecular biology and cell biology, as well as in new imaging technologies. The focus of this presentation will be nuclear-based molecular-genetic imaging, but it will comment on the value and utility of combining different imaging modalities. Nuclear-based molecular imaging can be viewed in terms of three different imaging strategies: (1) "indirect" reporter gene imaging; (2) "direct" imaging of endogenous molecules; or (3) "surrogate" or "bio-marker" imaging. Examples of each imaging strategy will be presented and discussed. The rapid growth of in vivo molecular imaging is due to the established base of in vivo imaging technologies, the established programs in molecular and cell biology, and the convergence of these disciplines. The development of versatile and sensitive assays that do not require tissue samples will be of considerable value for monitoring molecular-genetic and cellular processes in animal models of human disease, as well as for studies in human subjects in the future. Noninvasive imaging of molecular-genetic and cellular processes will complement established ex vivo molecular-biological assays that require tissue sampling, and will provide a spatial as well as a temporal dimension to our understanding of various diseases and disease processes.     

Animal models of infection and inflammation and their role in experimental nuclear medicine

In this review, basic aspects of nuclear medicine are described. One of the fields of research in nuclear medicine is the development of new radiopharmaceuticals for imaging infection and inflammation in humans. For this development, animal models are identified and modified to needs of a particular research question. In this review, a wide variety of models that are available in our laboratory are presented and the strengths and pitfalls are discussed.     

Somatic cell nuclear transfer: Past, present and future perspectives

It is now over a decade since the birth, in 1996, of Dolly the first animal to be produced by nuclear transfer using an adult derived somatic cell as nuclear donor. Since this time similar techniques have been successfully applied to a range of species producing live offspring and allowing the development of transgenic technologies for agricultural, biotechnological and medical uses. However, though applicable to a range of species, overall, the efficiencies of development of healthy offspring remain low. The low frequency of successful development has been attributed to incomplete or inappropriate reprogramming of the transferred nuclear genome. Many studies have demonstrated that such reprogramming occurs by epigenetic mechanisms not involving alterations in DNA sequence, however, at present the molecular mechanisms underlying reprogramming are poorly defined. Since the birth of Dolly many studies have attempted to improve the frequency of development, this review will discuss the process of animal production by nuclear transfer and in particular changes in the methodology which have increased development and survival, simplified or increased robustness of the technique. Although much of the discussion is applicable across species, for simplicity we will concentrate primarily on published data for cattle, sheep, pigs and mice.     

Bone scintigraphy for cardiac amyloidosis imaging: Past,present and future

The aim of the article was to review the history of the emergence of ^99mTc-labeled phosphate agents in the exploration of cardiac amyloidosis and the give an overview of the technique, its accuracy and its application in clinical practice. Potential future directions are mentioned.     

Effective dose from radiation exposure in medicine: Past,present, and future

Effective dose (E) has been developed by the International Commission on Radiological Protection (ICRP) as a dose quantity with a link to risks of health detriment, mainly cancer. It is based on reference phantoms representing average individuals, but this is often forgotten in its application to medical exposures, for which its use sometimes goes beyond the intended purpose. There has been much debate about issues involved in the use of E in medicine and ICRP is preparing a publication with more information on this application. This article aims to describe the development of E and explain how it should be used in medicine. It discusses some of the issues that arise when E is applied to medical exposures and provides information on how its use might evolve in the future. The article concludes with responses to some frequently asked questions about uses of E that are in line with the forthcoming ICRP publication. The main use of E in medicine is in meaningful comparison of doses from different types of procedure not possible with measurable dose quantities. However, it can be used, with appropriate care, as a measure of possible cancer risks. When considering E to individual patients, it is important to note that the dose received will differ from that assessed for reference phantoms, and the risk per Sv is likely to be greater on average in children and less in older adults. Newer techniques allow the calculation of patient-specific E which should be distinguished from the reference quantity.     

Polychaete systematics: Past and present

In this paper, we first demonstrate the historical background for the current unsatisfactory state of systematics of the polychaetes. We then briefly discuss our knowledge of internal and external structures. A review of the polychaete families makes up the third section; 81 families are treated in detail. Five families have been recently synonymized with others, and six families are too poorly known to be sufficiently characterized. Fossil polychaetes are briefly mentioned, with specific attention to problems associated with incorporating them in recent systematics.
The traditional separation in 'errant' and 'sedentary' polychaetes has increasingly become recognized as being unsatisfactory; however, the current trend towards grouping the polychaetes in many orders without specifying the relationships among the orders, is no more satisfactory. The lack of consistent morphological information is a major source of uncertainty. Intensive morphological studies should remove terminological ambiguities and alleviate some of the problems.     

Yeast phytases: present scenario and future perspectives

Phytases hydrolyze phytates to liberate soluble and thus readily utilizable inorganic phosphate. Although phytases are produced by various groups of microbes, yeasts being simple eukaryotes and mostly non-pathogenic with proven probiotic benefits can serve as ideal candidates for phytase research. The full potential of yeast phytases has not, however, been exploited. This review focuses attention on the present status of knowledge on the production, characterization, molecular characteristics, and cloning and over-expression of yeast phytases. Several potential applications of the yeast phytases in feeds and foods, and in the synthesis of lower myo-inositol phosphates are also discussed.     

Glycoproteomics: Past, present and future

This invited paper reviews the study of protein glycosylation, commonly known as glycoproteomics, beginning with the origins of the subject area in the early 1970s shortly after mass spectrometry was first applied to protein sequencing. We go on to describe current analytical approaches to glycoproteomic analyses, with exemplar projects presented in the form of the complex story of human glycodelin and the characterisation of blood group H eptitopes on the O-glycans of gp273 from Unio elongatulus. Finally, we present an update on the latest progress in the field of automated and semi-automated interpretation and annotation of these data in the form of GlycoWorkBench, a powerful informatics tool that provides valuable assistance in unravelling the complexities of glycoproteomic studies.     

p120-catenin: Past and present

p120-catenin was first described in 1989 as a Src substrate whose phosphorylation correlated with transformation. It was identified by cDNA cloning in 1992, and shown to interact with cadherins in 1994. Though enigmatic for some time, p120 has emerged as a master regulator of cadherin stability, and an important modulator of RhoGTPase activities. With the discovery of p120 family members and evidence for fundamental roles in cell biology and cancer, the field has expanded dramatically in recent years. As an introduction to this collection of reviews on p120 and its relatives, the editors have requested a personal commentary and historical perspective on the discovery of p120. The anecdotal parts have no particular purpose, but are mostly unpublished and perhaps of interest to some.     

Past, present and future of hemophilia: a narrative review

ABSTRACT: Over the past forty years the availability of coagulation factor replacement therapy has greatly contributed to the improved care of people with hemophilia. Following the blood-borne viral infections in the late 1970s and early 1980, caused by coagulation factor concentrates manufactured using non-virally inactivated pooled plasma, the need for safer treatment became crucial to the hemophilia community. The introduction of virus inactivated plasma-derived coagulation factors and then of recombinant products has revolutionized the care of these people. These therapeutic weapons have improved their quality of life and that of their families and permitted home treatment, i.e., factor replacement therapy at regular intervals in order to prevent both bleeding and the resultant joint damage (i.e. primary prophylaxis). Accordingly, a near normal lifestyle and life-expectancy have been achieved. The main current problem in hemophilia is the onset of alloantibodies inactivating the infused coagulation factor, even though immune tolerance regimens based on long-term daily injections of large dosages of coagulation factors are able to eradicate inhibitors in approximately two-thirds of affected patients. In addition availability of products that bypass the intrinsic coagulation defects have dramatically improved the management of this complication. The major challenges of current treatment regimens, such the short half life of hemophilia therapeutics with need for frequent intravenous injections, encourage the current efforts to produce coagulation factors with more prolonged bioavailability. Finally, intensive research is devoted to gene transfer therapy, the only way to ultimately obtain cure in hemophilia.     

Past, present and future of atomic force microscopy in life sciences and medicine

To introduce this special issue of the Journal of Molecular Recognition dedicated to the applications of atomic force microscopy (AFM) in life sciences, this paper presents a short summary of the history of AFM in biology. Based on contributions from the first international conference of AFM in biological sciences and medicine (AFM BioMed Barcelona, 19-21 April 2007), we present and discuss recent progress made using AFM for studying cells and cellular interactions, probing single molecules, imaging biosurfaces at high resolution and investigating model membranes and their interactions. Future prospects in these different fields are also highlighted.